Sign In
Buy ZLAB
$17.17
+0.0200 (+0.117%)
At Close: Jun 03, 2026
Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
05:16pm, Friday, 21'st Mar 2025
Zai Lab Limited is an innovative Pharma partnering with US and European Pharmas to secure approvals for, and market their drugs in China. ZLAB stock has surged over 105% in the past year, driven by st
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
01:05pm, Thursday, 20'th Mar 2025
ZLAB's Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB's main growth drivers. ZLAB's ongoing strategy of focusing on Chinese approval
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet
10:55am, Tuesday, 04'th Mar 2025
The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e
Zai Lab Announces Participation in Investor Conferences in March 2025
07:30am, Monday, 03'rd Mar 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor
Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript
10:46pm, Thursday, 27'th Feb 2025
Zai Lab Limited (NASDAQ:ZLAB ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Head of Investor Relations Samantha Du - Foun
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
06:00am, Thursday, 27'th Feb 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highligh
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?
11:25am, Monday, 24'th Feb 2025
Zai Lab Limited (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down
Here's Why 'Trend' Investors Would Love Betting on Zai Lab Limited (ZLAB)
09:50am, Monday, 24'th Feb 2025
Zai Lab Limited (ZLAB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed throug
Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade
10:56am, Tuesday, 28'th Jan 2025
The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
07:30am, Tuesday, 28'th Jan 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
11:15pm, Wednesday, 22'nd Jan 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-131
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
07:30am, Friday, 17'th Jan 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Applicat
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study,
SHANGHAI & CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and
